

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

| |
|---|
| OMB APPROVAL |
| OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 |
| SEC FILE NUMBER 001-21990 |
| CUSIP NUMBER |

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR

For Period Ended: December 31, 2020

- Transition Report on Form 10-K
 Transition Report on Form 20-F
 Transition Report on Form 11-K
 Transition Report on Form 10-Q
 Transition Report on Form N-SAR

For the Transition Period Ended: _____

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Oncotelic Therapeutics, Inc.

Full Name of Registrant

Former Name if Applicable

29397 Agoura Road Suite 107

Address of Principal Executive Office (*Street and Number*)

Agoura Hills, California, 91301

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Oncotelic Therapeutics, Inc. ("Oncotelic" or "Our") is unable to file, without unreasonable effort or expense, our Annual Report on Form 10-K ("Form 10-K") for the year ended December 31, 2020 by the prescribed filing date because it is still in the process of completing its audit of the financial statements required to be included in the Form 10-K. Oncotelic currently expects that it will be able to complete the audit necessary in time for the Company to file the Form 10-K within the fifteen calendar day extension provided by Rule 12b-25.

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

